Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Jones Trading Downgrades Theravance Biopharma (TBPH) to Hold
June 29, 2026 6:01 AM EDT
Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million, according to a press release issued June 29, 2026.
Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other... More
June 29, 2026 6:00 AM EDT
Zymeworks Inc. (NASDAQ: ZYME) announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH) at $17.00 per share in cash, representing a total transaction value of approximately $929 million, subject to customary adjustments.
The acquisition adds YUPELRI (revefenacin), a nebulized long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease,... More
